Cohance Lifesciences Limited — Q1 FY26
Cohance Life Sciences reported Q1 FY26 revenue growth of 13% YoY, with pharma CDMO growing over 30% excluding inventory destocking.
bullish
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
67%Questions answered3Evaded / deflected12Questions auditedContradictedNumbers vs filing
Answered
Medium priority
Are API intermediates exported to US or Europe?
Asked by Anish Burman, Vicaria
Directly answered the destination region.
Read the exchange
Question
I wanted to know whether you are exporting these APIs um into facilities in the US or are they majorly being exported into some European countries like Ireland and the population is happening there.
Himmanu (management)
Predominantly Europe.
Answered
High priority
Are APIs/intermediates subject to US tariffs?
Asked by Anish Burman, Vicaria
Clearly stated intermediates are exempt from tariffs.
Read the exchange
Question
Is this understanding correct that APIs that are being imported into the US are getting tariffed as of now?
Himmanu (management)
We don't make APIs, we do intermediates and they are right now not part of the tariffs that are being talked about. As far as we are aware, pharma is exempt and right now we are exempt from any tariff discussion.
Answered
High priority
If tariffs apply, who bears the cost?
Asked by Anish Burman, Vicaria
Explained FOB basis means customer bears tariff.
Read the exchange
Question
Is there an agreement or an understanding on how will it get passed on in the supply chain whether your customer will bear it or whether you will have to bear a part of it?
Himmanu (management)
Most of our current agreements with the customers are on FOB basis we do not have the liability to pay the tariff when the goods reach the shore of US.
Answered
Medium priority
What is BD team strength and future hiring plans?
Asked by Dal, Jeff
Provided specific numbers and locations.
Read the exchange
Question
What is our current BD team strength especially overseas and where are these teams located and what is the future plan? Do we still see lot of aggressive hiring within these teams?
Himmanu (management)
In North America we have four BDs. These are all experienced CDMO several of them are PhDs that we have hired in the last nine months or so. They are based in East Coast and West Coast. We also have added a resource in Europe as well as one very seasoned executive to the Japanese market.
Answered
Medium priority
Do innovators know payload source when CDMO supplies?
Asked by Dal, Jeff
Clearly stated innovator is aware and involved.
Read the exchange
Question
In those cases does the end innovator know where is the payload coming from or is it completely at the discretion of the global CDMO?
Himmanu (management)
Final decision is fully with the innovator and innovator is fully aware and it's part of the decision making process on selection of the products that we supply.
Answered
Medium priority
Will Cohance explore mAb manufacturing?
Asked by Dal, Jeff
Explicitly stated no plans for mAb.
Read the exchange
Question
Do you think mAb manufacturing looks a area that we would like to explore if any inorganic opportunity comes up or even trying to build it organically?
Himmanu (management)
Our focus is to grow with customer and invest with customers. We haven't seen much need and desire actually for customer to really partner with us on that space. Right now we're not looking any mAb capabilities to acquire and invest.
Answered
High priority
Is destocking specific to a few products?
Asked by Harid Ahmed, Aventas Park
Specified exactly two molecules.
Read the exchange
Question
Is this specific to a particular product or one or two products or are you referring to a destocking situation which is more general across the portfolio?
Himmanu (management)
The destocking that you referred to is specific to few products. It's related to two large commercial molecules that we are experiencing the destocking right now.
Partial answer
Medium priority
How does oligo expansion enhance capabilities?
Asked by Harid Ahmed, Aventas Park
Described direction but lacked quantitative details.
no specific capacity numbersvague on timeline
Read the exchange
Question
How exactly this expansion enhances our offering on the oligo side? What exactly are we capable of supplying now versus what will be our enhanced capability going forward post the expansion?
Harit Prasad (management)
Our starting point of oligo is predominantly research-driven and the important requirement for us is to have cGMP capabilities. We have figured out nucleotides is one modality subsegment they are looking for. This is the first step of our business progression.
Partial answer
Medium priority
How will NJ Bio expand to commercial scale conjugation?
Asked by Harid Ahmed, Aventas Park
Explained potential but no concrete commitment.
no timeline for commercial scaleconditional on customer progress
Read the exchange
Question
When I look at our payload capabilities we already supply commercial at commercial scale. So now how should we think about our further enhancing our bio conjugation capabilities to commercial scale?
Himmanu (management)
We have facility available very close to Princeton and NJ Bio which can be converted at a very fast pace to build commercial capability. It's actually a semi-built facility that is already ready in a pharma park.
Evasive
High priority
Why confidence in FY26 margin guidance despite Q1 miss?
Asked by Shamsawasan, Goldman Sachs
Did not address how Q2-Q4 will achieve 30% margin.
reframed to long-term guidanceno specific FY26 margin path
Read the exchange
Question
Margins have come in lower... 23-24% we have guided for a low 30% kind of margin. So what gives us the confidence? How should the rest of the quarters pan out and what gives us the confidence of the guidance for fiscal 26 remains intact?
Himmanu (management)
We have reiterated our guidance both for FY26 and more importantly for the FY30 or 2030 $1 billion. If you isolate the destocking, pharma CDMO has grown at around 30%. We should not interpret anything from a quarter to quarter business.
Deflected
High priority
What is the organic growth and margin guidance for FY26?
Asked by Shamsawasan, Goldman Sachs
Avoided giving organic growth or margin numbers.
refused to separate organic/inorganicno specific numbers given
Read the exchange
Question
What are we calling for organic growth for fiscal 26 full year and what is the margin levels that we're expecting to full year fiscal 26.
Himmanu (management)
For us the organic and inorganic are two sides of the same coin. It's about capital allocation. I would urge you guys to kind of think about it in the way we look at and not separating it as an organic or inorganic.
Evasive
Medium priority
When will one-time expenses stop appearing?
Asked by Chaksha, White Pine Investments Management
Did not commit to any cessation of one-time costs.
no timeline givendeflected to business nature
Read the exchange
Question
When can we expect them to not appear in P&L? Is this the last year assuming there are no further M&A or is there a last quarter?
Himmanu (management)
It's very difficult for me to answer a question about when they can disappear. I mean I would be as interested as you that they disappear but that's the current nature of the business.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Pharma CDMO grew around 30% excluding destocking | 30% | 13% | Overstated vs filing |
| Specialty chemicals growing at 28% | 28% | 13% | Overstated vs filing |
| API growing at 90% | 90% | 13% | Overstated vs filing |
| FY30 revenue target of $1 billion or 85 billion INR | ₹85,000 cr | ₹549.31 cr | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.